No Data
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Guiyang Xintian Pharmaceutical (002873.SZ): Received 29 trademark registration certificates, 3 trademark renewal registration certificates, and 1 appearance design patent certificate.
On March 26, GELONGHUI reported that Guiyang Xintian Pharmaceutical (002873.SZ) announced that recently, Guiyang Xintian Pharmaceutical Co., Ltd. received 29 newly issued trademark registration certificates, 3 trademark renewal registration certificates, and 1 design patent certificate from the National Intellectual Property Administration.
Xintian Pharmaceutical Completes License Amendment
Guiyang Xintian Pharmaceutical (002873.SZ): Change of Pharmaceutical production license.
On March 19, Gelonghui reported that Guiyang Xintian Pharmaceutical (002873.SZ) announced that the company applied for a change in the "Pharmaceutical Production License" due to its production and operation needs, adding entrusted production qualifications and category code changes. This matter has been approved and recently the company received a new "Pharmaceutical Production License" issued by the Guizhou Provincial Drug Supervision Administration. The main content of this change in the company's "Pharmaceutical Production License" is the addition of "entrusted production" qualifications. The client is Guizhou Qian Pharmaceutical Group Co., Ltd. (formerly known as Guizhou Yao Xiaozai Pharmaceutical Co., Ltd.), located at a registered address in the Yunyan District of Guiyang City, Guizhou Province, in the Zhongjian Huafu area on Dayingpo Street.
Guiyang Xintian Pharmaceutical (002873.SZ): Huilun Pharmaceutical has obtained the registration certificate for the pharmaceutical product of Empagliflozin and Metformin Extended-Release Tablets.
Gelonghui reported on March 3 that Guiyang Xintian Pharmaceutical (002873.SZ) announced that its associate company Shanghai Huilun Pharmaceutical Co., Ltd. (referred to as "Huilun Pharmaceutical") recently received the Drug Registration Certificate (certificate number: 2025S00532) approved and issued by the National Medical Products Administration for the empagliflozin and metformin extended-release tablets. The empagliflozin and metformin extended-release tablets are a compound formulation of empagliflozin and metformin, mainly used to lower blood sugar and effectively control type Ⅱ diabetes. The product combines the advantages of empagliflozin and metformin through different blood sugar-lowering mechanisms.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Market Might Still Lack Some Conviction On Guiyang Xintian Pharmaceutical Co.,Ltd. (SZSE:002873) Even After 45% Share Price Boost
